White Paper

Accelerating The Development Of Enabled Formulations For Poorly Soluble Drugs Using Translational Pharmaceutics®

Source: Quotient Sciences
Pharm Manufacturing Facility GettyImages-1087218874

New drugs advancing through development often face efficacy issues caused by insufficient aqueous solubility. The traditional in-vitro analysis and pre-clinical studies used are notoriously poor at predicting drug behavior in humans, and  the cost and time expended in this process can be considerable. The selection of formulation prototypes to overcome a solubility issue using these tools also carries a significant risk of non-resolution in subsequent clinical testing.

Explore how the Translational Pharmaceutics® platform — which integrates drug substance, drug product and clinical testing activities within a single organization — accelerates development timelines and reduces project costs, helping deliver positive clinical outcomes earlier.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader